Evidence map›Paper›PMID 32535047›Full record

ArticleGene2020

Multiple domains in the 50 kDa form of E4F1 regulate promoter-specific repression and E1A trans-activation.

Robert J Rooney

Open access · greenAbstract read
In one paragraph

Article in Gene, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact, top 93% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 0 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Robert J RooneyDepartment of Genetics, Duke University Medical Center, Durham, NC, USA. Electronic address: rrooney1@uthsc.edu.
Duke University · US

Funding

STRUCTURE AND REGULATION OF THE E4F TRANSCRIPTION FACTORR01GM051299 · NIGMS · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI ROONEY, ROBERT J · 1995 to 1999
–
NIGMS NIH HHS R01 GM051299
6 · The paper itself

Abstract

The 50 kDa N-terminal product of the cellular transcription factor E4F1 (p50E4F1) mediates E1A289R trans-activation of the adenovirus E4 gene, and suppresses E1A-mediated transformation by sensitizing cells to cell death. This report shows that while both E1A289R and E1A243R stimulate p50E4F1 DNA binding activity, E1A289R trans-activation, as measured using GAL-p50E4F1 fusion proteins, involves a p50E4F1 transcription regulatory (TR) region that must be promoter-bound and is dependent upon E1A CR3, CR1 and N-terminal domains. Trans-activation is promoter-specific, as GAL-p50E4F1 did not stimulate commonly used artificial promoters and was strongly repressive when competing against GAL-VP16. p50E4F1 and E1A289R stably associate in vivo using the p50E4F1 TR region and E1A CR3, although their association in vitro is indirect and paradoxically disrupted by MAP kinase phosphorylation of E1A289R, which stimulates E4 trans-activation in vivo. Multiple cellular proteins, including TBP, bind the p50E4F1 TR region in vitro. The mechanistic implications for p50E4F1 function are discussed.

Indexed as

Gene Expression RegulationPromoter Regions, GeneticTranscriptional ActivationAdenovirus E1A ProteinsBinding SitesHEK293 CellsHeLa CellsHumansPhosphorylationProtein DomainsRepressor ProteinsTranscription, GeneticUbiquitin-Protein LigasesAdenovirus E1A ProteinsE4F1 protein, humanRepressor ProteinsUbiquitin-Protein LigasesAdenovirus E1A oncogeneE4F1 transcription factorTrans-activationTranscriptional repressor

Identifiers

PMID32535047
PMCPMC7394487
OpenAlexW3034272539

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.